The angiogenic profile of colorectal cancer patients following open or laparoscopic colectomy

Cancer Biology and Therapy

Volumn 10, Issue 7, 2010, Pages 686-688

  Voloshin, Tali ^a   Gingis Velitski, Svetlana ^a   Shaked, Yuval ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Angiogenesis; Bone marrow derived proangiogenic cells; Circulating biomarkers; Vascular damage; Wound healing

Indexed keywords

CD133 ANTIGEN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; APOPTOSIS; CANCER SURGERY; CELL COUNT; CELL VIABILITY; COLON RESECTION; COLORECTAL CANCER; COMPARATIVE STUDY; ENDOTHELIUM CELL; HUMAN; LAPAROSCOPIC SURGERY; NONHUMAN; NOTE;

APOPTOSIS; CELL SURVIVAL; COLECTOMY; COLORECTAL NEOPLASMS; ENDOTHELIAL CELLS; HUMANS; LAPAROSCOPY; PARTICLE SIZE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 77957584725     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.7.13240     Document Type: Note

References (19)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-49.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth H, Helm W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42. (Pubitemid 38702844)
4. Shaked Y, Voest EE. Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil? Biochim Biophys Acta 2009; 1796:1-4.
5. Madlambayan GJ, Butler JM, Hosaka K, Jorgensen M, Fu D, Guthrie SM, et al. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood 2009; 114:4310-9.
6. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, et al. VEGF-induced adult neovascularization: recruitment, retention and role of accessory cells. Cell 2006; 124:175-89. (Pubitemid 43069318)
7. Bertolini F, Mancuso P, Braidotti P, Shaked Y, Kerbel RS. The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochim Biophys Acta 2009; 1796:27-32.
8. Bertolini F, Marighetti P, Shaked Y. Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy. Biochim Biophys Acta 2010; Epub ahead of print.
9. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108:452-9.
10. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, et al. Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res 2009; 15:7652-7.
11. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. J Clin Oncol 2008.
12. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. Nature Rev Cancer 2006; 6:835-45.
13. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7:101-11. (Pubitemid 40126386)
14. Shaked Y, Emmengger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106:3058-61. (Pubitemid 41565900)
15. Bono A, Bianchi P, Locatelli A, Calleri A, Quarna J, Antoniott P, et al. Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs. open surgery for colorectal cancer. Cancer Bio1 Ther 2010; 10:682-85.
16. Wu FP, Hoekman K, Sietses C, von Blomberg BM, Meijer S, Bonjer HJ, et al. Systemic and peritoneal angiogenic response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. Dis Colon Rectum 2004; 47:1670-4. (Pubitemid 39331980)
17. Condon ET, Barry BD, Wang JH, Kirwan WO, Redmond HP. Laparoscopic surgery protects against the oncologic adverse effects of open surgery by attenuating endothelial progenitor cell mobilization. Surg Endosc 2007; 21:87-90.
18. Wagman LD. Laparoscopic and open surgery for colorectal cancer: reaching equipoise? J Clin Oncol 2007; 25:2996-8.
19. Kang SB, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010; 11:637-45.